Global Oncology Drugs Market Overview And Scope:
Global Oncology Drugs Market Size was estimated at USD 218219.46 million in 2022 and is projected to reach USD 395165.22 million by 2028, exhibiting a CAGR of 10.4% during the forecast period.
The Global Oncology Drugs Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Oncology Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson and Johnson, Merck and Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Global Oncology Drugs Market Segmentation
By Type, Oncology Drugs market has been segmented into:Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
By Application, Oncology Drugs market has been segmented into:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncology Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oncology Drugs market.
Top Key Players Covered in Oncology Drugs market are:
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson and Johnson
Merck and Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Objective to buy this Report:
1. Oncology Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Oncology Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Oncology Drugs Market by Type
5.1 Oncology Drugs Market Overview Snapshot and Growth Engine
5.2 Oncology Drugs Market Overview
5.3 Chemotherapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Chemotherapy: Geographic Segmentation
5.4 Targeted Therapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Targeted Therapy: Geographic Segmentation
5.5 Immunotherapy (Biologic Therapy)
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Immunotherapy (Biologic Therapy): Geographic Segmentation
5.6 Hormonal Therapy
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Hormonal Therapy: Geographic Segmentation
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation
Chapter 6: Oncology Drugs Market by Application
6.1 Oncology Drugs Market Overview Snapshot and Growth Engine
6.2 Oncology Drugs Market Overview
6.3 Blood Cancer
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Blood Cancer: Geographic Segmentation
6.4 Breast Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Breast Cancer: Geographic Segmentation
6.5 Gastrointestinal Cancer
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Gastrointestinal Cancer: Geographic Segmentation
6.6 Prostate Cancer
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Prostate Cancer: Geographic Segmentation
6.7 Respiratory or Lung Cancer
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Respiratory or Lung Cancer: Geographic Segmentation
6.8 Others
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2017-2032F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Oncology Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Oncology Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ROCHE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CELGENE
7.4 NOVARTIS
7.5 BRISTOL-MYERS SQUIBB
7.6 JOHNSON AND JOHNSON
7.7 MERCK AND CO.
7.8 ASTRAZENECA
7.9 PFIZER
7.10 AMGEN
7.11 ELI LILLY
7.12 ABBVIE
7.13 TAKEDA
7.14 ASTELLAS
7.15 IPSEN
7.16 SANOFI
7.17 BAYER
7.18 BIOGEN IDEC
7.19 TEVA
7.20 OTSUKA
7.21 EISAI
7.22 MERCK KGAA
7.23 GILEAD SCIENCES
Chapter 8: Global Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Chemotherapy
8.2.2 Targeted Therapy
8.2.3 Immunotherapy (Biologic Therapy)
8.2.4 Hormonal Therapy
8.2.5 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Blood Cancer
8.3.2 Breast Cancer
8.3.3 Gastrointestinal Cancer
8.3.4 Prostate Cancer
8.3.5 Respiratory or Lung Cancer
8.3.6 Others
Chapter 9: North America Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Chemotherapy
9.4.2 Targeted Therapy
9.4.3 Immunotherapy (Biologic Therapy)
9.4.4 Hormonal Therapy
9.4.5 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Blood Cancer
9.5.2 Breast Cancer
9.5.3 Gastrointestinal Cancer
9.5.4 Prostate Cancer
9.5.5 Respiratory or Lung Cancer
9.5.6 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Chemotherapy
10.4.2 Targeted Therapy
10.4.3 Immunotherapy (Biologic Therapy)
10.4.4 Hormonal Therapy
10.4.5 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Blood Cancer
10.5.2 Breast Cancer
10.5.3 Gastrointestinal Cancer
10.5.4 Prostate Cancer
10.5.5 Respiratory or Lung Cancer
10.5.6 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Chemotherapy
11.4.2 Targeted Therapy
11.4.3 Immunotherapy (Biologic Therapy)
11.4.4 Hormonal Therapy
11.4.5 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Blood Cancer
11.5.2 Breast Cancer
11.5.3 Gastrointestinal Cancer
11.5.4 Prostate Cancer
11.5.5 Respiratory or Lung Cancer
11.5.6 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Chemotherapy
12.4.2 Targeted Therapy
12.4.3 Immunotherapy (Biologic Therapy)
12.4.4 Hormonal Therapy
12.4.5 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Blood Cancer
12.5.2 Breast Cancer
12.5.3 Gastrointestinal Cancer
12.5.4 Prostate Cancer
12.5.5 Respiratory or Lung Cancer
12.5.6 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Chemotherapy
13.4.2 Targeted Therapy
13.4.3 Immunotherapy (Biologic Therapy)
13.4.4 Hormonal Therapy
13.4.5 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Blood Cancer
13.5.2 Breast Cancer
13.5.3 Gastrointestinal Cancer
13.5.4 Prostate Cancer
13.5.5 Respiratory or Lung Cancer
13.5.6 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Oncology Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Chemotherapy
14.4.2 Targeted Therapy
14.4.3 Immunotherapy (Biologic Therapy)
14.4.4 Hormonal Therapy
14.4.5 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Blood Cancer
14.5.2 Breast Cancer
14.5.3 Gastrointestinal Cancer
14.5.4 Prostate Cancer
14.5.5 Respiratory or Lung Cancer
14.5.6 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Oncology Drugs Scope:
|
Report Data
|
Oncology Drugs Market
|
|
Oncology Drugs Market Size in 2025
|
USD XX million
|
|
Oncology Drugs CAGR 2025 - 2032
|
XX%
|
|
Oncology Drugs Base Year
|
2024
|
|
Oncology Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson and Johnson, Merck and Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences.
|
|
Key Segments
|
By Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
By Applications
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
|
